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DoAlthough the use of oral anticoagulants (vitamin K antagonists) has been abandoned in primary cardiovascular prevention
due to lack of a favorable beneﬁt-to-risk ratio, the indications for aspirin use in this setting continue to be a source of
major debate, with major international guidelines providing conﬂicting recommendations. Here, we review the evidence
in favor and against aspirin therapy in primary prevention based on the evidence accumulated so far, including recent
data linking aspirin with cancer protection. While awaiting the results of several ongoing studies, we argue for a prag-
matic approach to using low-dose aspirin in primary cardiovascular prevention and suggest its use in patients at high
cardiovascular risk, deﬁned as $2 major cardiovascular events (death, myocardial infarction, or stroke) projected per
100 person-years, who are not at increased risk of bleeding. (J Am Coll Cardiol 2014;64:319–27) © 2014 by the American
College of Cardiology Foundation. Open access under CC BY-NC-ND license.m the *De
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320(GI) bleeding and hemorrhagic stroke (6). As
a result, guidelines and other expert opin-
ions differ substantially in their recommen-
dations for primary prevention, reﬂecting
the uncertainty of a precise risk/beneﬁt ra-
tio in this population.
This document, produced by a committee
appointed by the European Society of Car-
diology (ESC) Working Group on Throm-
bosis, reviews and discusses the most
up-to-date evidence for the safety and efﬁ-cacy of aspirin use in primary CVD prevention, with the
main aim of issuing practical recommendations.
METHODS
We searched the electronic PubMed database for
randomized controlled trials (RCTs) or meta-analyses
of RCTs using the following terms: anticoagulants OR
aspirin OR antiplatelet drugs AND primary prevention
AND coronary heart disease OR cardiovascular dis-
ease OR coronary artery disease OR peripheral arterial
disease (PAD) OR cancer OR all-cause mortality. The
last literature searches were performed on February
28, 2014. The authors critically evaluated the evi-
dence, with an assessment of the risk/beneﬁt ratio.
The strength of recommendation and level of evi-
dence of particular treatment options were weighed
and graded according to the ESC system (7).
ASSESSING BASELINE RISK
In primary CVD prevention, in which the risk of
developing atherothrombotic events is generally low,
it is essential to estimate the individual baseline risk
of such events and carefully balance this against the
risk of adverse outcomes related to therapy.
Commonly-used tools to assess baseline risk are the
Framingham coronary heart disease (CHD) risk score
(8), the recently released American College of Cardi-
ology/American Heart Association (AHA/ACC) Task
Force risk equations (9), ESC’s SCORE (Systematic
Coronary Risk Evaluation), or national risk charts.
Some tools assess the risk of cardiovascular death,
whereas others assess all major cardiovascular
events. The Framingham CHD risk score predicts
the 10-year risk of developing a coronary eventconsultancies/presentations from Bayer; and has served as an
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dividuals are categorized as low (<10%), moderate
(10% to 20%), or high (>20%) risk. Conversely, the
SCORE system, recommended in the ESC guidelines
(7), estimates the 10-year risk of a fatal atherosclerotic
event: individuals are considered at low risk with
a SCORE <1%, at moderate risk with a SCORE $1%
and <5%, at high risk with a SCORE $5% and <10%,
and at very high risk with a SCORE $10% (7).
Clearly, the risk of total fatal and nonfatal events is
higher than that of fatal events only. At a 5% risk of
fatal events, the total event risk is approximately
15% (7). This 3-fold multiplier is somewhat smaller
in the elderly, in whom a ﬁrst event is more likely
to be fatal.
ASPIRIN IN PRIMARY CVD PREVENTION
The only antithrombotic drugs investigated for pri-
mary CVD prevention are vitamin K antagonists,
which were investigated in only 1 trial and are
currently abandoned (Online Appendix), and acetyl
salicylic acid (aspirin). Aspirin has been studied in 9
large-scale RCTs (10–18), including more than
100,000 participants (Table 1, Online Appendix).
META-ANALYSES OF PRIMARY CVD PREVENTION
TRIALS WITH ASPIRIN. The meta-analysis carried
out by the ATT (Anti-Thrombotic Trialists) Collabo-
ration in 2009 (6) included the ﬁrst 6 primary pre-
vention trials (10–15) (n ¼ 95,000) and demonstrated
that, over a 10-year period, aspirin therapy was
associated with 6 fewer MIs per 1,000 low-risk per-
sons treated (5% CHD risk at 10 years according to the
Framingham risk categories). For persons at moderate
(15%) and high (25%) CHD risk, aspirin led to a
reduction of 19 and 31 MIs per 1,000 patients treated,
respectively (8). The downside was that the risk of
bleeding events was also higher as a function of car-
diovascular risk. Thus, the overall reduction of MIs
was almost balanced by the increase in bleeding
events throughout baseline risk categories. Aspirin
therapy did not seem to have an effect on stroke
occurrence. With respect to mortality, there was a
small protective effect of aspirin therapy, with 0 to
6 fewer deaths per 1,000 persons treated over
10 years. This protective effect on mortality was
found to be of similar magnitude in persons at lowadvisor to Boehringer Ingelheim, Bayer Healthcare,
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ria from Boehringer Ingelheim, Bayer, BMS/Pﬁzer,
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TABLE 1 Characteristics of Individual Trials of Aspirin in Primary Prevention
Trial, Year Participants Male, % Mean Age, yrs Aspirin Dose, mg
Duration of
Follow-Up, yrs* Primary Endpoint
BDT, 1988 5,139 100 63.6 500 or 300 daily 6.0 MI, stroke, or CV death
PHS, 1989 22,071 100 53.8 325 alternate day 5.02 MI, stroke, or CV death
HOT, 1998 18,790 53 61.5 75 daily 3.8 Major CV events
TPT, 1998 5,085 100 57.5 75 daily 6.4 Major coronary event
PPP, 2001 4,495 42 64.4 100 daily 3.6 MI, stroke, or CV death
WHS, 2005 39,876 0 54.6 100 alternate day 10.1 MI, stroke, or CV death
POPADAD, 2008 1,276 44 60.3 100 daily 6.7 CV death, MI, stroke, or amputation
JPAD, 2008 2,539 55 64.5 81 or 100 daily 4.37 Any atherosclerotic event
AAA, 2010 3,350 28 61.6 100 daily 8.2 Fatal or nonfatal coronary event,
stroke, or revascularization
*Duration of follow-up represents median follow-up for POPADAD and JPAD, mean follow-up for the other trials.
AAA ¼ Aspirin for Asymptomatic Atherosclerosis; BDT ¼ British Doctors Trial; CV ¼ cardiovascular; HOT ¼ Hypertension Optimal Treatment; JPAD ¼ Japanese Primary
Prevention of Atherosclerosis With Aspirin for Diabetes; MI ¼ myocardial infarction; PHS ¼ Physicians Health Study; POPADAD ¼ Prevention of Progression of Arterial Disease
and Diabetes; PPP ¼ Primary Prevention Project; TPT ¼ Thrombosis Prevention Trial; WHS ¼ Women’s Health Study.
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321and at moderate-to-high risk for atherothrombotic
events. Since bleeding risk appeared to be strongly
related to the ischemic risk, the beneﬁt of aspirin was
judged to be overshadowed by the bleeding hazard. If
aspirin were to be combined with other agents that
would halve the risk of a major ischemic event, such
as statins (19), the potential beneﬁt of aspirin would
be almost completely abolished.
Four additional meta-analyses have recently been
performed by other groups, and published in 2011 to
2012 (20–23). In all of them, 3 additional trials were
included: the JPAD (Japanese Primary Prevention of
Atherosclerosis With Aspirin for Diabetes), POPADAD
(Prevention of Progression of Arterial Disease and
Diabetes), and AAA (Aspirin for Asymptomatic Ath-
erosclerosis) trials (16–18) (Table 1). These trials were
somewhat nonhomogeneous with the previous ones,
as they included individuals who, although asymp-
tomatic, were at higher risk because of pre-existing
diabetes, asymptomatic PAD, or both. In these meta-
analyses, all-cause—but not vascular—mortality was
slightly but consistently reduced, reiterating a risk
ratio of 0.94 with uniform conﬁdence limits (0.88 to
1.00), but without reaching formal signiﬁcance. These
ﬁgures compare well with those of the ATT meta-
analysis (conﬁdence limits: 0.88 to 1.02) (6). The
claim for a signiﬁcant reduction of mortality is not
formally justiﬁed by the data and is possibly
misleading (24,25).
In patients with asymptomatic PAD, a recent sys-
tematic review (26) conﬁrmed that no differences
were observed between aspirin and placebo for total
and vascular mortality, MI, and stroke. In abdominal
aortic aneurysms, a recent Cochrane systematic re-
view (27) on pharmacological prevention of car-
diovascular events did not include studies withantiplatelet agents, because any eligible studies failed
to pass the quality assessment phase. Thus, there is
no proof that, in asymptomatic PAD or asymptomatic
aortic aneurysms alone, the use of aspirin confers an
advantage over not using aspirin in CVD prevention.
ADVERSE EVENTS WITH ASPIRIN. The most common
adverse effect associated with aspirin is bleeding. The
meta-analysis by the ATT Collaboration found that
allocation to aspirin increased major GI and other
extracranial bleeds (deﬁned “as a bleed requiring
transfusion or resulting in death”) by about 50%
(0.10%/year vs. 0.07%/year; risk ratio: 1.54 [95% CI:
1.30 to 1.82], p < 0.0001) (6). Recently, it has been
emphasized that the bleeding risk is higher in in-
dividuals at higher cardiovascular risk over 10 years.
Compared with placebo, this high-risk population
would experience 22 more bleeds per 1,000 persons
treated with aspirin versus 4 more bleeds per 1,000
persons treated with aspirin in the low-risk popula-
tion (8).
Aspirin also increases the risk of hemorrhagic
stroke. A meta-analysis of 16 placebo-controlled
RCTs, comprising a total of 55,462 patients, showed
that treatment with aspirin was associated with a
relative risk of hemorrhagic stroke of 1.84 (p < 0.001)
(28). In absolute terms, one could predict 12 incident
cases of hemorrhagic stroke per 10,000 patients
chronically treated with aspirin (29). The ATT
Collaboration reported a statistically signiﬁcant 22%
increased incidence of hemorrhagic stroke in patients
on antiplatelet treatment (30).
ASPIRIN FOR PRIMARY CVD PREVENTION IN DIABETES.
Patients with diabetes have a 2 to 4 greater risk of
cardiovascular events than individuals of the same
age and sex without diabetes (31,32). Data by Haffner
TABLE 2 Number of Events Averted or Incurred Should 10,000
Persons Be Treated With Aspirin in Primary CVD Prevention
and Followed-Up for 10 Years
Range Mean
Events averted
Deaths (any cause) 33–46 39.5
MCE (CV death, MI, or stroke) 60–84 72.0
Total CHD events 47–64 55.5
CRC deaths 34–36 35.0
Cancer deaths 17–85 51.0
Events incurred
Major bleeds 46–48 47.0
GI bleeds 117–182 149.5
Hemorrhagic strokes 8–10 9.0
Table reprinted with permission from Sutcliffe et al. (25).
CHD ¼ coronary heart disease; CRC ¼ colorectal cancer; GI ¼ gastrointestinal;
MCE ¼ major cardiovascular event(s); other abbreviations as in Table 1.
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322et al. (33) suggest that there is a similar risk of future
CHD events for both diabetic subjects without prior
CHD and nondiabetic subjects with previous CHD
(33). However, a meta-analysis of 13 studies,
involving 45,108 patients (34), showed that the car-
diovascular risk of diabetic patients without previous
CVD is signiﬁcantly lower than that of nondiabetic
patients with previous CVD (34). Three RCTs con-
ducted speciﬁcally in patients with diabetes
(16,18,35) and 6 RCTs in which patients with diabetes
were trackable subgroups (1% to 22%) (10–15) failed
to provide deﬁnitive results on the effect of aspirin
in primary CVD prevention. A meta-analysis of these
9 RCTs found that aspirin was associated with sta-
tistically nonsigniﬁcant reductions of CHD events
(9%) and of cerebrovascular events (11%) (31).
Three other meta-analyses found similar estimates
(36–38). Based on the overall negative results of
these RCTs, it is generally assumed that aspirin is
less effective in patients with diabetes than in in-
dividuals without diabetes. However, the individual
patient-level meta-analysis by the ATT Collabora-
tion showed that the effect of aspirin on major
cardiovascular events was similar for participants
with and without diabetes (risk ratios: 0.88 [95%
conﬁdence interval (CI): 0.67 to 1.15] and 0.87 [95%
CI: 0.79 to 0.96], respectively) (6). The wider 95%
CI for diabetes is attributable to its smaller repre-
sentation (about 4,000 patients with diabetes vs.
about 91,000 without diabetes) (6).
NEW DATA ON ASPIRIN IN PREVENTION OF CANCER.
In the past 10 years, the notion of a favorable non-
cardiovascular effect of aspirin in preventing cancer-
related mortality has progressively gained
consensus. First observed for colorectal cancer, the
effect was later reported for other malignancies,
especially adenocarcinomas. In a meta-analysis by
Rothwell et al. (39), 8 RCTs (not homogeneous as to
the level of cardiovascular risk and aspirin doses [75
to 650 mg daily], in both primary and secondary CVD
prevention) found that cumulative total mortality
was 10.2% in aspirin users versus 11.1% in nonusers
(odds ratio: 0.92, 95% CI: 0.85 to 1.00). The hazard
ratio, which was calculated in a time-dependent
analysis in 7 of the 8 trials, was 0.82, a signiﬁcant
total mortality reduction (95% CI: 0.70 to 0.95).
Reduction in cancer mortality was a driving force for
this, and became especially relevant after 5 years
(hazard ratio: 0.66) and persisted even after 20 years
for GI and other solid cancers (hazard ratio: 0.65).
Regular, daily administration of aspirin for the
entire trial duration appeared to be necessary to
confer the beneﬁt. These data were reinforced byanother more recent meta-analysis of 11 RCTs,
mainly of secondary CVD prevention with low-dose
aspirin (75 to 325 mg daily), yielding a signiﬁcant
reduction in cancer mortality (risk ratio: 0.77, 95%
CI: 0.63 to 0.95) (40). Similar results for cancer
incidence were obtained by pooling 6 trials of pri-
mary CVD prevention (odds ratio: 0.76, 95% CI:
0.66 to 0.88) (41), and conﬁrmed by data from the
Women’s Health Study (42).
THE NET CLINICAL BENEFIT. The net clinical beneﬁt
of giving aspirin to healthy individuals is made difﬁ-
cult to assess by the imprecision of estimates of
beneﬁts and risks, especially for rare events, such as
intracranial hemorrhage, and by the difﬁculty of
weighing ischemic versus bleeding events. A recent
extensive systematic review of aspirin in primary
prevention concludes that “there is a ﬁne balance
between beneﬁts and risks from regular aspirin use in
primary prevention of cardiovascular disease” (25).
However, although the number of ischemic events
averted (on average: 72 averted by treating 10,000
patients for 10 years) was similar to the number of
major bleeding events incurred (on average: 47
events), aspirin use would be associated with about
40 deaths averted against an average of 9 hemor-
rhagic strokes incurred, with an apparent overall
beneﬁt (Table 2).
CURRENT GUIDELINES
The 2012 ESC (7) and the American College of Chest
Physicians (ACCP) (8) guidelines have addressed the
issue of aspirin in primary CVD prevention with
different conclusions. According to the ESC guidelines,
Major CV events
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FIGURE 1 Relationships Between Magnitude of Antithrombotic Beneﬁt and of
Bleeding Risk Connected With the Use of Aspirin, and Absolute Cardiovascular Risk,
in Various Subsets of Subjects in Primary Prevention
To examine the strength of the association between treatment effects of aspirin on car-
diovascular events, major gastrointestinal bleeding, and total major bleeding with the level
of cardiovascular risk per 100 person-years in the control arm of the trials, we ﬁtted uni-
variate inverse variance-weighted linear regressions of the risk difference for the outcome
events per 100 person-years between the 2 experimental arms of each study as a dependent
variable against the aforementioned explanatory variable. The size of circles is proportional
to the inverse of variance of the risk difference. Red arrow denotes the area where beneﬁt
likely equals risk, yellow area denotes area of prescription uncertainty, and green arrow
denotes the area where beneﬁt most likely exceeds risk. Continuous line¼ linear regression;
dotted line ¼ lower and higher 95% conﬁdence interval (CI). Trials included: U.S. PHS
(Physicians Health Study) (13), BDT (British Doctors Trial) (10), TPT (Thrombosis Prevention
Trial) (14), HOT (Hypertension Optimal Treatment) study (15), PPP (Primary Prevention
Project) (12), Women’s Health Study (11), POPAPDAD study (Prevention of Progression of
Arterial Disease and Diabetes) (18), JPAD study (16), and the AAA (Aspirin for Asymptomatic
Atherosclerosis) trial (17). Data from the Swedish Angina Pectoris Aspirin Trial
also are included (47). Further details can be found in the Online Appendix.
ASA ¼ acetylsalicylic acid (aspirin); CV ¼ cardiovascular; GI ¼ gastrointestinal.
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323aspirin or clopidogrel “is not recommended in in-
dividuals without cardiovascular or cerebrovascular
disease” due to the increased risk of major bleeding
(Class III, Level of Evidence: B) (7). Conversely, the
ACCP guidelines suggest low-dose aspirin 75 to 100
mg daily for persons age 50 years or older without
symptomatic CVD (Grade 2B) (8), remarking that
aspirin slightly reduces total mortality regardless of
cardiovascular risk proﬁle if taken over 10 years. In
people at moderate-to-high risk of cardiovascular
events, the reduction in MIs is closely balanced by an
increase in major bleeds, prompting aspirin use in
individuals who value preventing an MI substantially
more than avoiding a GI bleed.
Concerning diabetes, the ACCP guidelines suggest
that the relative beneﬁt of aspirin is similar in patients
with and without diabetes. The American Diabetes
Association, the AHA, and the ACC (31) recommend as
follows:
1. Primary cardiovascular prevention with aspirin is
reasonable in diabetic patients whose 10-year risk
of events is >10% (men age >50 years and women
age >60 years with at least 1 additional risk factor:
smoking, hypertension, dyslipidemia, albumin-
uria, or family history of premature cardiovascular
events) and who are not at increased risk of
bleeding (no history of gastrointestinal bleeding or
peptic ulcer disease, no concurrent use of other
medications that increase bleeding risk).
2. Aspirin should not be recommended in diabetes
patients at low risk of cardiovascular events,
because the potential adverse effects from bleeding
offset the potential beneﬁts.
3. Aspirin may be considered for diabetes patients at
intermediate risk of cardiovascular events (younger
patients with at least 1 risk factor, older patients
with no risk factors, or patients with a 10-year risk
of 5% to 10%).ONGOING STUDIES
For information regarding ongoing studies, please see
Online Table 2. Most aspirin trials for primary CVD
prevention have enrolled individuals at low cardio-
vascular risk, with estimated coronary event rates
<1% per person-years. To ﬁll a missing gap, 5 ongoing
RCTs are investigating the safety and efﬁcacy of 100
mg aspirin daily versus placebo (or vs. no aspirin) in
more than 60,000 men and women at a higher level of
cardiovascular risk, that is, without known CVD but
with estimated rates of coronary events of 1% to 2%
per person-years (or of total cardiovascular events
w3% per person-years). In all 5 RCTs, the primaryefﬁcacy outcome includes vascular death, nonfatal
MI, and nonfatal stroke to be weighed against major
bleeding (mainly GI and intracranial) and other
adverse events. The duration of follow-up is 4 to 7.5
years or driven by the number of accrued events. The
enrolled populations range from nondiabetic subjects
with $2 or $3 risk factors, to elderly patients age $70
years (43), elderly (age 60 to 85 years) with additional
risk factors (44), and individuals with diabetes
(ASCEND: A Study of Cardiovascular Events iN Dia-
betes; NCT00135226) or with diabetes taking a statin
(45). ENVIS-ion (Aspirin for the Prevention of Cogni-
tive Decline in the Elderly: A Neuro-Vascular Imaging
Study) is a substudy of the ASPREE (Aspirin in
TABLE 3 Arguments for and Against the Use of Aspirin in Primary Prevention
Contra Pro
Bleeds induced numerically equal ischemic
events prevented.
Although this may be true in some of the
primary prevention studies, this is unlikely to
hold for high-risk primary prevention, in
which no data are so far available and
projections (Fig. 1) would indicate an NNH
higher than the NNT.
Bleeds induced have a similar prognostic
implication as ischemic events averted.
This is, with the exception of the rare
occurrence of intracranial hemorrhage
(approximately one-ﬁfth of all major bleeds),
unlikely to be true, as nonfatal ischemic
events averted are mostly “spontaneous”
myocardial infarctions and (ischemic) strokes.
Patients’ preferences: most patients would
prefer nonfatal major bleeding to a nonfatal
myocardial infarction or stroke.
Aspirin may reduce the risk of cancer in the
long-term, extending the beneﬁt beyond
CVD prevention, and so far is underestimated
in the relatively short follow-up of CVD
prevention studies.
Risk estimates based on relatively old charts
or algorithms (e.g., the Framingham Risk
Score, or the European Society of
Cardiology SCORE) may overestimate
the current risk of CVD.
This is an unavoidable limitation of all analyses
based on risk calculations. The effect is
likely—in any case—to be minor.
CVD ¼ cardiovascular disease; NNH ¼ number needed to harm; NNT ¼ number needed to treat;
SCORE ¼ Systematic Coronary Risk Evaluation.
Halvorsen et al. J A C C V O L . 6 4 , N O . 3 , 2 0 1 4
Aspirin Therapy in Primary CVD Prevention J U L Y 2 2 , 2 0 1 4 : 3 1 9 – 2 7
324Reducing Events in the Elderly) study, investigating
the effects of aspirin versus placebo on brain lesions
assessed by magnetic resonance imaging after 3 years
of treatment (46).
TAILORING THERAPY ACCORDING TO BASELINE
RISK IS STILL THE BEST CURRENT PRACTICAL
GUIDANCE. In primary CVD prevention, where the
risk of developing atherothrombotic events for each
individual patient is generally low, it is essential
to estimate the individual baseline risk of such
events and to carefully balance this against the side
effects of therapy, in this case bleeding. Cardio-
vascular risk can be viewed as a continuum,
increasing from primary prevention in young totally
healthy individuals, to high-risk primary preven-
tion, and then to secondary prevention (Fig. 1).
There is indeed no theoretical reason or any evi-
dence suggesting a discontinuity of aspirin effects
throughout these categories. The beneﬁt of treatment
(savingmajor cardiovascular events) is clearly superior
to the risk (inducing major bleeding) in the setting of
secondary cardiovascular prevention. In the lowest
risk category of secondary prevention, the stable
angina population investigated in the Swedish Angina
Pectoris Aspirin Trial (47), the use of aspirin 75 mg/day
was associated with a signiﬁcant 32% reduction in
vascular events, a 35% increase in major bleeding, and
9 versus 5 fatal bleeds in the aspirin and placebo
groups, respectively, and was judged to be clearlyfavorable, with 118 vascular events prevented versus
10 patients lost through fatal bleeds for 10,000
patient-years of treatment (47).
It is hard to imagine that, going down the spectrum
of cardiovascular risk from secondary to primary pre-
vention, there would be an immediate drop of the risk/
beneﬁt ratio making aspirin use suddenly unappeal-
ing. Nature usually does not make jumps. Indeed, a
graphical evaluation of the beneﬁt-risk balance, as
portrayed in Figure 1, indicates a large area of cardio-
vascular risk in primary prevention where data from
trials are lacking, but in whom the beneﬁt may still
outweigh the risk. The ongoing trials will try to answer
this question. In the meantime, however, taking into
account the logical argument of the continuum in pri-
mary and secondary prevention, the argument raised
that for the entire primary prevention “the balance
between vascular events avoided and major bleeds
caused by aspirin is substantially uncertain because
the risks without aspirin, and hence the absolute
beneﬁts of antiplatelet prophylaxis, are at least an or-
der of magnitude lower than in secondary prevention”
(48) should not be raised generically.
Additional considerations (Table 3) mostly prompt
aspirin use in primary prevention. Particularly
worthy of additional discussion are the following:
1. Most models attribute equal weight in terms of
patient preference to a nonfatal cardiovascular
event (MI and ischemic stroke) and to major
bleeding. With the exception of the rare occurrence
of hemorrhagic stroke, this is hard to concede.
Although not at all negligible in terms of conse-
quences for deaths and disabilities (49), the risk of
hemorrhagic stroke appears to be around one-ﬁfth
of all major bleeding events incurred because of
aspirin use (Online Table 1), and its fatal conse-
quences are already comprised in total deaths es-
timates associated with aspirin use, which points
toward a net beneﬁt (25).
2. The alleged sex differences, proposed for the
aspirin-related protection from cardiovascular
events (11), do not seem to hold when the entire
evidence is reviewed and analyzed (6).
It is, however, probable that risk scores developed
some years ago do not reﬂect—and likely over-
estimate—the current situation of cardiovascular
risk, which has decreased over time for a variety of
reasons, including the implementation of effective
prevention strategies, such as lifestyle measures,
statins, angiotensin-converting enzyme inhibitors,
and angiotensin receptor blockers. These treatments
target atherothrombosis upstream of thrombosis-
related events, and therefore, compress part of the
Step 1: Assess 10 year 
risk of major CV events <10% 10-20% >20%
Step 2: history of bleeding without 
reversible causes, concurrent use of 
other medications that increase 
bleeding risk
Consider family 
history of GI
(especially colon) cancer
/patient values and
Low-dose aspirin
preferences
Stop
Go ahead with caution
Proceed
CENTRAL ILLUSTRATION A Proposed Practical Stepwise Approach to the Use of
Aspirin in Primary CV Prevention
The ﬁrst step should be an assessment of patient’s eligibility to the treatment, by
assessing the 10-year risk of major cardiovascular (CV) events (death, myocardial
infarction, and stroke), according to local population risk estimates. Eligible patients will
be those with an estimated 10-year risk >20%. Patients with a 10-year risk between
10% and 20% will be deemed as “potentially eligible,” and those with a risk <10% will
be considered noneligible. The second step will be assessing safety in eligible and
potentially-eligible patients, through a history of bleeding without reversible causes, and
concurrent use of other medications that increase bleeding risk. In the absence of such
conditions, patients with a risk >20% should be given low-dose aspirin, and those with
a risk 10% to 20% should be engaged in a case-by-case discussion, factoring family
history of gastrointestinal cancer (especially colon cancer) and patient values and
preferences; particularly motivated patients can then be prescribed low-dose aspirin.
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325aspirin beneﬁt. Such an argument has been raised
to recommend these nonantithrombotic treatments
as alternative to, rather than complementary to
aspirin (6). We argue, however, that there are still
categories for individuals in primary prevention
featuring the level of risk above a certain threshold,
and in these a substantial number of major cardio-
vascular events are likely to be preventable by
aspirin with a reasonable efﬁcacy/safety balance.
DEFINING THE THRESHOLD. Thus, we should iden-
tify a threshold risk level above which recommending
aspirin is expected to produce more beneﬁt than risk.
We propose such a threshold at a risk of major car-
diovascular events (death, MI, and stroke) $2 per 100
patient-years, assessed through the most accurate and
country-speciﬁc risk factor estimates. Such a proposal
is: 1) logically derived from the previously-described
evidence; and 2) a conservative one, privileging
safety rather than efﬁcacy. Upon inspection of
Figure 1, one could argue that the lines depicting the
risk-level dependence of beneﬁt and risk diverge even
earlier than the 2 per 100 patient-years level. How-
ever, there are wide conﬁdence intervals of such es-
timates. Therefore, an “uncertainty area” should be
indicated, at risk levels between 1 and 2 per 100
patient-years, in which the decision to prescribe or
not to prescribe aspirin is left to the physician’s
discretion and to the patient’s preferences (Central
Illustration).
The general principles upon which such a proposal
is drawn are shared by several other groups (8,31),
although threshold levels for recommendation vary.
Our proposed threshold level is higher, and therefore,
more conservative than that proposed by the U.S.
Preventive Task Force (50) (0.6 per 100 patient-years)
and suggested by the AHA ($1 per 100 patient-years)
(51). It is also signiﬁcantly higher than the current
recommendation from the ACCP (8), which suggests
low-dose aspirin daily for all persons age $50 years
without symptomatic CVD. The proposed threshold
risk level of 2 major cardiovascular events/100
patient-years, corresponding approximately to a
SCORE risk of 7% to 10% at 10 years (6,8), is sufﬁ-
ciently conservative to allow a net cardiovascular
beneﬁt to be achieved. The reported beneﬁt of aspirin
in also preventing noncardiovascular deaths in the
long term, such as death due to cancer, can only
reinforce such recommendations while waiting for
deﬁnite proof-of-concept through the completion of
properly-designed clinical trials.
Beyond routine screenings, we also recommend
that additional evidence of risk can be used to prompt
doctors and patients to adopt antithrombotic therapy
with aspirin in conditions of indecision (52). We alsorecommend that, after careful transferring of the
relevant information to patients, individual values
and preferences should be taken into account.
We recognize that across the entire area of high
cardiovascular risk in primary prevention, and espe-
cially in high-risk primary prevention ($2 major car-
diovascular events per 100 patient-years) (Fig. 1), it is
opportune to acquire more data through other
placebo-controlled trials, some of which are already
ongoing. Particularly problematic areas include dia-
betic patients or patients with asymptomatic PAD.
The mere presence of either does not appear sufﬁ-
cient for aspirin to confer a beneﬁt clearly exceeding
the risk.
CONCLUSIONS AND RECOMMENDATIONS
We recommend that aspirin use in the primary pre-
vention of acute MI and other atherothrombotic
cardiovascular events in subjects of both sexes is
guided by an assessment of the underlying cardio-
vascular risk (Grade of Recommendation: I, Level of
Evidence: B) (Central Illustration). We suggest that
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326aspirin be considered in the primary prevention of
CVD in both sexes at a level of risk of major cardio-
vascular events (death, MI, and stroke) >2 per 100
subject-years, provided they have no clear evidence
of increased risk of bleeding (GI bleeding or peptic
ulcer disease, no concurrent use of other medications
that increase bleeding risk) (Class of Recommenda-
tion: IIa, Level of Evidence: B).ACKNOWLEDGMENT The authors thank Dr.
Marco Scarano for help in the data extraction and the
drawing of the Central Illustration.
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